Amygdala dynorphin/κ opioid receptor system modulates depressive-like behavior in mice following chronic social defeat stress. 2022

Gui-Ying Zan, and Xiang Sun, and Yu-Jun Wang, and Rui Liu, and Chen-Yao Wang, and Wei-Jia Du, and Liu-Bin Guo, and Jing-Rui Chai, and Qing-Lin Li, and Zhi-Qiang Liu, and Jing-Gen Liu
Department of Anesthesiology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, China.

Major depression disorder is a severe and recurrent neuropsychological disorder characterized by lowered mood and social activity and cognitive impairment. Owing to unclear molecular mechanisms of depression, limited interventions are available in clinic. In this study we investigated the role of dynorphin/κ opioid receptor system in the development of depression. Mice were subjected to chronic social defeat stress for 14 days. Chronic social defeat stress induced significant social avoidance in mice characterized by decreased time duration in the interaction zone and increased time duration in the corner zone. Pre-administration of a κ opioid receptor antagonist norBNI (10 mg/kg, i.p.) could prevent the development of social avoidance induced by chronic social defeat stress. Social avoidance was not observed in κ opioid receptor knockout mice subjected to chronic social defeat stress. We further revealed that social defeat stress activated c-fos and ERK signaling in the amygdala without affecting the NAc, hippocampus and hypothalamus, and ERK activation was blocked by systemic injection of norBNI. Finally, the expression of dynorphin A, the endogenous ligand of κ opioid receptor, was significantly increased in the amygdala following social defeat stress; microinjection of norBNI into the amygdala prevented the development of depressive-like behaviors caused by social defeat stress. The present study demonstrates that upregulated dynorphin/κ opioid receptor system in the amygdala leads to the emergence of depression following chronic social defeat stress, and sheds light on κ opioid receptor antagonists as potential therapeutic agents for the prevention and treatment of depression following chronic stress.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009271 Naltrexone Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Antaxone,Celupan,EN-1639A,Nalorex,Naltrexone Hydrochloride,Nemexin,ReVia,Trexan,EN 1639A,EN1639A
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D004399 Dynorphins A class of opioid peptides including dynorphin A, dynorphin B, and smaller fragments of these peptides. Dynorphins prefer kappa-opioid receptors (RECEPTORS, OPIOID, KAPPA) and have been shown to play a role as central nervous system transmitters. Dynorphin,Dynorphin (1-17),Dynorphin A,Dynorphin A (1-17)
D000083703 Social Defeat Conflict between members of the same species that generates emotional and psychological stress and increased social distance. Defeat, Social
D000679 Amygdala Almond-shaped group of basal nuclei anterior to the INFERIOR HORN OF THE LATERAL VENTRICLE of the TEMPORAL LOBE. The amygdala is part of the limbic system. Amygdaloid Body,Amygdaloid Nuclear Complex,Amygdaloid Nucleus,Archistriatum,Corpus Amygdaloideum,Intercalated Amygdaloid Nuclei,Massa Intercalata,Nucleus Amygdalae,Amygdalae, Nucleus,Amygdaloid Bodies,Amygdaloid Nuclear Complices,Amygdaloid Nuclei, Intercalated,Amygdaloid Nucleus, Intercalated,Amygdaloideum, Corpus,Amygdaloideums, Corpus,Archistriatums,Complex, Amygdaloid Nuclear,Complices, Amygdaloid Nuclear,Corpus Amygdaloideums,Intercalata, Massa,Intercalatas, Massa,Intercalated Amygdaloid Nucleus,Massa Intercalatas,Nuclear Complex, Amygdaloid,Nuclear Complices, Amygdaloid,Nuclei, Intercalated Amygdaloid,Nucleus, Amygdaloid,Nucleus, Intercalated Amygdaloid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors
D012919 Social Behavior Any behavior caused by or affecting another individual or group usually of the same species. Sociality,Behavior, Social,Behaviors, Social,Social Behaviors

Related Publications

Gui-Ying Zan, and Xiang Sun, and Yu-Jun Wang, and Rui Liu, and Chen-Yao Wang, and Wei-Jia Du, and Liu-Bin Guo, and Jing-Rui Chai, and Qing-Lin Li, and Zhi-Qiang Liu, and Jing-Gen Liu
September 2023, Addiction biology,
Gui-Ying Zan, and Xiang Sun, and Yu-Jun Wang, and Rui Liu, and Chen-Yao Wang, and Wei-Jia Du, and Liu-Bin Guo, and Jing-Rui Chai, and Qing-Lin Li, and Zhi-Qiang Liu, and Jing-Gen Liu
October 2015, Behavioural pharmacology,
Gui-Ying Zan, and Xiang Sun, and Yu-Jun Wang, and Rui Liu, and Chen-Yao Wang, and Wei-Jia Du, and Liu-Bin Guo, and Jing-Rui Chai, and Qing-Lin Li, and Zhi-Qiang Liu, and Jing-Gen Liu
May 2019, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Gui-Ying Zan, and Xiang Sun, and Yu-Jun Wang, and Rui Liu, and Chen-Yao Wang, and Wei-Jia Du, and Liu-Bin Guo, and Jing-Rui Chai, and Qing-Lin Li, and Zhi-Qiang Liu, and Jing-Gen Liu
January 2012, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Gui-Ying Zan, and Xiang Sun, and Yu-Jun Wang, and Rui Liu, and Chen-Yao Wang, and Wei-Jia Du, and Liu-Bin Guo, and Jing-Rui Chai, and Qing-Lin Li, and Zhi-Qiang Liu, and Jing-Gen Liu
March 2023, Biomolecules & therapeutics,
Gui-Ying Zan, and Xiang Sun, and Yu-Jun Wang, and Rui Liu, and Chen-Yao Wang, and Wei-Jia Du, and Liu-Bin Guo, and Jing-Rui Chai, and Qing-Lin Li, and Zhi-Qiang Liu, and Jing-Gen Liu
March 2020, Brain and behavior,
Gui-Ying Zan, and Xiang Sun, and Yu-Jun Wang, and Rui Liu, and Chen-Yao Wang, and Wei-Jia Du, and Liu-Bin Guo, and Jing-Rui Chai, and Qing-Lin Li, and Zhi-Qiang Liu, and Jing-Gen Liu
July 2015, Acta pharmacologica Sinica,
Gui-Ying Zan, and Xiang Sun, and Yu-Jun Wang, and Rui Liu, and Chen-Yao Wang, and Wei-Jia Du, and Liu-Bin Guo, and Jing-Rui Chai, and Qing-Lin Li, and Zhi-Qiang Liu, and Jing-Gen Liu
October 2011, Pharmacology, biochemistry, and behavior,
Gui-Ying Zan, and Xiang Sun, and Yu-Jun Wang, and Rui Liu, and Chen-Yao Wang, and Wei-Jia Du, and Liu-Bin Guo, and Jing-Rui Chai, and Qing-Lin Li, and Zhi-Qiang Liu, and Jing-Gen Liu
August 2019, Biochemical and biophysical research communications,
Gui-Ying Zan, and Xiang Sun, and Yu-Jun Wang, and Rui Liu, and Chen-Yao Wang, and Wei-Jia Du, and Liu-Bin Guo, and Jing-Rui Chai, and Qing-Lin Li, and Zhi-Qiang Liu, and Jing-Gen Liu
November 2023, Nature communications,
Copied contents to your clipboard!